{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:15:24Z","timestamp":1787019324955,"version":"build-2736575974"},"reference-count":30,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D. The objective of this secondary analysis was to evaluate rifaximin retreatment on IBS-related QOL in patients with IBS-D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients received open-label rifaximin 550 mg three times daily for 2 weeks. Clinical responders [simultaneously meeting weekly response criteria for abdominal pain (\u2a7e30% improvement from baseline in mean weekly pain score) and stool consistency (\u2a7e50% decrease from baseline in number of days\/week with Bristol Stool Scale (BSS) type 6 or 7 stools) during \u2a7e2 of first 4 weeks posttreatment] who relapsed during an up to 18-week treatment-free observation phase were randomly assigned to receive two 2-week courses of double-blind rifaximin or placebo, separated by 10 weeks. A validated 34-item IBS-QOL questionnaire examined patient responses in 8 domains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The 2579 patients receiving open-label rifaximin experienced a mean improvement from baseline in IBS-QOL overall score of 54.9%. Responders to open-label rifaximin ( n = 1074 of 2438 evaluable; 44.1%) had significantly greater improvement from baseline in IBS-QOL overall and all eight subdomain scores, including dysphoria, food avoidance, interference with activity, body image, and sexual function versus nonresponders at 4 weeks posttreatment ( n = 1364; p &lt; 0.001 for all comparisons). A significantly greater percentage of responders to open-label rifaximin achieved the minimally clinically important difference (MCID; \u2a7e14-point improvement from baseline) in the overall IBS-QOL score versus nonresponders [ n = 561 (52.2%) versus n = 287 (21.0%); p &lt; 0.0001]. Among 636 patients with IBS-D relapse, the MCID in the overall IBS-QOL score was achieved by a significantly greater percentage of patients receiving double-blind rifaximin versus placebo (38.6% versus 29.6%, respectively; p = 0.009).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Open-label and blinded retreatment with a short course (2 weeks) of rifaximin improved IBS-QOL in patients with IBS-D [ClinicalTrials.gov identifier: NCT01543178].<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1756283x17726087","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T07:44:36Z","timestamp":1505115876000},"page":"689-699","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":23,"title":["Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1177","volume":"10","author":[{"given":"Brooks D.","family":"Cash","sequence":"first","affiliation":[{"name":"University of South Alabama, Digestive Health Center, 75 S. University Blvd, Suite 6000-B, Mobile, AL 36608, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Pimentel","sequence":"additional","affiliation":[{"name":"GI Motility Program, Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish S. C.","family":"Rao","sequence":"additional","affiliation":[{"name":"Section of Gastroenterology\/Hepatology, Digestive Health Center, Medical College of Georgia Augusta University, Augusta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Specialists in Gastroenterology, LLC, Washington University School of Medicine, St Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Digestive Diseases\/Gastroenterology, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeev","family":"Heimanson","sequence":"additional","affiliation":[{"name":"Salix Pharmaceuticals, Bridgewater, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lembo","sequence":"additional","affiliation":[{"name":"Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,9,11]]},"reference":[{"key":"bibr1-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.031"},{"key":"bibr2-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2013.19.9.755"},{"key":"bibr3-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2000.16484"},{"key":"bibr4-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.061"},{"key":"bibr5-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.201"},{"key":"bibr6-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02463.x"},{"key":"bibr7-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318189a7f9"},{"key":"bibr8-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1186\/1757-4749-2-19"},{"key":"bibr9-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2012.01891.x"},{"key":"bibr10-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.04.005"},{"key":"bibr11-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13236"},{"key":"bibr12-1756283X17726087","first-page":"512","volume":"22","author":"Tana C","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"bibr13-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12460"},{"key":"bibr14-1756283X17726087","first-page":"412","volume":"98","author":"Pimentel M","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"bibr15-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004409"},{"key":"bibr16-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.08.003"},{"key":"bibr17-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.08.026"},{"key":"bibr18-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02165-16"},{"key":"bibr19-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.14309\/00000434-201510001-01790"},{"key":"bibr20-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.2.272"},{"key":"bibr21-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01283.x"},{"key":"bibr22-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018831127942"},{"key":"bibr23-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i26.8103"},{"key":"bibr24-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-015-0243-3"},{"key":"bibr25-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.105"},{"key":"bibr26-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(97)00118-9"},{"key":"bibr27-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505180"},{"key":"bibr28-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05208.x"},{"key":"bibr29-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03525.x"},{"key":"bibr30-1756283X17726087","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-11-208"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756283X17726087","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1756283X17726087","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1756283X17726087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T14:09:04Z","timestamp":1741010944000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1756283X17726087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1177\/1756283X17726087"],"URL":"https:\/\/doi.org\/10.1177\/1756283x17726087","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}